ReviewWorld journal of hepatology2021
Racial differences in prevalence and severity of non-alcoholic fatty liver disease.
Review in World journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Deregulated miR-487b-3p in Patients with Non-Alcoholic Fatty Liver Disease and Its Regulatory Effect on Insulin Resistance.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Cross-sectional Study in Asymptomatic Individuals in Greater Vancouver.Journal of clinical and translational hepatology · 2025Article
- Cultural and Molecular Factors Predisposed to Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Nutrients · 2025Review
- Disparities in Alcohol-Associated Liver Disease Hospital Encounters Amongst a Texas-Based Cohort of Patients.Alimentary pharmacology & therapeutics · 2025Article
- Ruminococcus gnavus in the gut: driver, contributor, or innocent bystander in steatotic liver disease?The FEBS journal · 2025Review
- Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota.International journal of molecular sciences · 2024Review
- Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.World journal of gastroenterology · 2024Article
- The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.PloS one · 2024Article
- Article
- Risk factors and cardio-metabolic outcomes associated with metabolic-associated fatty liver disease in childhood.EClinicalMedicine · 2023Article
- Higher consumption of animal organ meat is associated with a lower prevalence of nonalcoholic steatohepatitis.Hepatobiliary surgery and nutrition · 2023Article
- Associations between residential volatile organic compound exposures and liver injury markers: The role of biological sex and race.Environmental research · 2023Article
- Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography.Hepatology research : the official journal of the Japan Society of Hepatology · 2023Article
- Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study.World journal of hepatology · 2023Article
- Association of the android to gynoid fat ratio with nonalcoholic fatty liver disease: a cross-sectional study.Frontiers in nutrition · 2023Article
- Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review.Nutrients · 2022Review
- Advances of microRNAs in regulating mitochondrial function: new potential application in NAFLD treatment.Molecular biology reports · 2022Review
- Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention.Current diabetes reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to assess the evidence regarding racial differences in the prevalence and severity of nonalcoholic fatty liver disease (NAFLD). We reviewed the published literature that reported prevalence, severity, and genetic associations of NAFLD in different ethnic groups. The metabolic syndrome (MetS) has been associated with NAFLD, but each component of the MetS is present in various races in different percentages and their effect on NAFLD appears to be dissimilar. An elevated triglyceride (TG) level seems to have the strongest association with NAFLD. The latter is more prevalent in Hispanic patients; Blacks have lower TG levels and a lower NAFLD prevalence, compared to Caucasians or Hispanics. The severity of liver fibrosis is lower in some, but not all biopsy-based studies of Black patients. No study has evaluated the severity of liver disease controlling for the individual components of MetS, especially TG. Important racial differences in the prevalence of selected genetic polymorphisms, particularly PNPLA-3 and MBOAT7 have been documented, together with their effects on the prevalence of liver steatosis and fibrosis. Data on overall and liver mortality have found no significant differences according to race/ethnicity, with the possible exception of one paper reporting lower cirrhosis mortality in Black patients. We conclude that NAFLD is more prevalent in Hispanics and less in Blacks. This is supported by differences in key genetic polymorphisms associated with hepatic fat storage. However, there is presently insufficient evidence to firmly conclude that race, per se, plays a role in the development of liver fibrosis and its complications. Further studies, appropriately controlled for diet, exercise, and individual MetS parameters are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.